Nice pickup on that one. Yeah, only 1 complete response was announced. One patient on 4GBq had 4 doses but not a complete response. They are in cohort 4 now so they would have done multiple doses on some patients already. Cohort 4 started on March but I am unsure on how long between doses.
Also what if cohort 3 patients can access EAP, they could have used a second dose for those patients.
Also, I believe AT will want to sell Clarity but the amount must be what the product can produce. I am just assuming, if Sar-bispsma can give complete responses for multiple patients, I don't believe $10B is the right amount. Wouldn't Clarity be better off doing a phase 3 trial and selling the product? My opionion only.
CU6 - Media and Industry News, page-218
-
- There are more pages in this discussion • 209 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.72 |
Change
-0.170(2.47%) |
Mkt cap ! $2.119B | |||
| Open | High | Low | Value | Volume |
| $6.95 | $7.25 | $6.68 | $28.33M | 4.127M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6509 | $6.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.78 | 6841 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |